Biocept to host key opinion leader webinar on october 14 to discuss its proprietary cnside™ assay to detect and quantify cancer that metastasized to the central nervous system

San diego--(business wire)--biocept, inc. (nasdaq: bioc), a leading provider of molecular diagnostic assays, products and services, announces an hour-long webinar to be held october 14 at 1 p.m. eastern time featuring case studies presented by leading neuro-oncologists who have used the company's cnside assay in the management of patients with confirmed or suspected central nervous system metastasis. the webinar will feature key opinion leaders priya u. kumthekar, md of northwestern university
BIOC Ratings Summary
BIOC Quant Ranking